| (210) | Number of the EPO application | 19758589 |
| (220) | Filing date of the EPO application | 2019.08.09 |
| (80) | EPO patent specification publication (B) | EPB nr. 45/2025, 2025.11.05 |
| (110) | EPO patent number | 4010322 |
| (21) | Number of the application | e 2022 0644 |
| (71) | Name(s) of applicant(s), code of the country | PFIZER INC., US; |
| (72) | Name(s) of inventor(s), code of the country | GREER Elaine, US;
ANDERSON Stephen, US;
MALONEY Mark, US;
YU Shu, US;
ALBERT Ekaterina, US;
RIGSBEE Emily, US; |
| (73) | Name(s) of owner(s), code of the country | Pfizer Inc., US; |
| (54) | Title of the invention | SOLID STATE FORMS OF (S)-2-(((S)-6,8-DIFLUORO-1,2,3,4-TETRAHYDRONAPHTHALEN-2-YL)AMINO)-N-(1-(2-METHYL-1-(NEOPENTYLAMINO)PROPAN-2-YL)-1H-IMIDAZOL-4-YL)PENTANAMIDE AND USES THEREOF |
| (13) | Kind-of-document code | A1 |
| (51) | International Patent Classification | C07D 233/88 (2006.01.01); A61K 31/4164 (2006.01.01); A61P 35/00 (2006.01.01) |
| (52) | Cooperative Patent Classification | C07D 233/88 (EP) |
| (19) | Country | US |
| (41) | Date of publication of the application | 2022.07.31 |
| (86) | International application | PCT/US2019/045948, 2019.08.09 |
| (87) | International publication | WO 2021/029854, 2021.02.18 |